Multicomponent MenB Vaccine (4CMenB): An Innovative Step In the Global Fight Against Serogroup B Meningococcal Disease
|
|
- Tyler Beasley
- 5 years ago
- Views:
Transcription
1 Multicomponent MenB Vaccine (4CMenB): An Innovative Step In the Global Fight Against Serogroup B Meningococcal Disease Jeffrey J. Stoddard, MD, FAAP Head, Global Medical Affairs Novartis Vaccines and Diagnostics
2 At-Risk Groups and Established Risk Factors Infants 1-2 Population with highest incidence (17.4-fold increase over average in Europe 3 ) Immature immune system Reduction of protective maternal antibody levels Adolescents 4-6 Population with highest carriage ( fold increase over other age groups 7 ) Close contact with a case Respiratory tract infection Smoking Crowding Dormitory Travel Concerts Most cases of meningococcal disease occur in previously healthy persons. 1. Rosenstein NE, et al. N Eng J Med. 2001;344: ; 2. Figueroa JE, et al. Clin Microbiol Rev. 1991;4: ; 3. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe 2008/2009. Stockholm: ECDC; 2011; 4. Bilukha OO, et al. MMWR Recomm Rep. 2005;54:1-21; 5. Imrey PB, et al. J Clin Microbiol. 1995;33: ; 6. Neal KR, et al. BMJ. 2000;320: ; 7. Christiansen H, et al. Lancet Infect Dis. 2010;10:
3 Conjugate Vaccines Against Meningitis-Causing Pathogens Have Been Successful Using the Polysaccharide Capsule H. influenzae (1 pathogenic type) S. pneumoniae (25 pathogenic serotypes) N. meningiditis (5 pathogenic serogroups) INVASIVE DISEASE INVASIVE DISEASE FULMINANT INVASIVE DISEASE A C W -135 Y B Hib glycoconjugate vaccine Pneumococcal glycoconjugate vaccine Meningococcal glycoconjugate vaccine No effective broadly, protective capsular vaccine 3
4 A Multicomponent Approach to MenB Vaccination The polysaccharide capsule? A single subcapsular protein component? Multiple subcapsular components? Poorly immunogenic Susceptible to antigenic variability Enables broad coverage across a number of strains N. meningitidis 4
5 Antigenic Components of the 4CMenB 4CMenB antigens are important for meningococcal survival, function, or virulence NadA: neisserial adhesin A Promotes adherence to and invasion of human epithelial cells 1-3 Possible importance in carriage fhbp: factor H binding protein Primary function: Binds the bacterial siderophore enterobactin (in vitro) 4 Secondary function: Binds factor H, which enables bacterial survival 5,6 NHBA: Neisseria heparinbinding antigen Present in virtually all strains Binds heparin, which may increase the serum resistance of bacteria 7-9 NZ PorA 1.4: porin A Major outer membrane vesicles protein produces robust antibody response 1. Comanducci M, et al. J Exp Med. 2002;195: ; 2. Capecchi B, et al. Mol Microbiol. 2005;55: ; 3. Mazzon C, et al. J Immunol. 2007;179: ; 4. Veggi D, et al. Presented at IPNC. Banff, Canada. September 11-16, 2010; 5. Madico G, et al. J Immunol. 2006;177: ; 6. Schneider MC, et al. J Immunol. 2006;176: ; 7. Serruto D, et al. Proc Natl Acad Sci U S A. 2010;107: ; 8. Welsch JA, et al. J Infect Dis. 2003;188: ; 9. Plested, et al. Clin Vaccine Immunol. 2008;15:
6 Vaccine composition 4CMenB: Vaccine Composition Antigenic Component Amount Recombinant Neisseria meningitidis serogroup B NHBA fusion protein Recombinant Neisseria meningitidis serogroup B NadA protein Recombinant Neisseria meningitidis serogroup B fhbp fusion protein Outer membrane vesicles (OMV) from Neisseria meningitidis serogroup B strain NZ98/254 measured as amount of total protein containing the PorA μg 50 μg 50 μg 25 μg Each component is adsorbed on aluminum hydroxide adjuvant 0.5 mg of Al +3 6
7 OMV Vaccination Eliminated the epidemic in New Zealand Auckland Rate per population Proof of principle that MenB vaccines can work and can be safely used 7
8 4CMenB Clinical Development Program 8 studies were conducted 6 studies in infants from 2 months of age and toddlers 3 studies in adolescents 11 years of age and adults 7,938 total subjects 6,354 infants and toddlers 1,630 received a booster dose in the second year of life 1,584 adolescents and adults Geographically diverse (EU, North and South America) 4CMenB has been studied in the Northern and Southern Hemispheres 8
9 4CMenB: Clinical Trial data Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307: Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379: Vesikari T, Esposito S, Kimura A, et al. Immunogenicity of an investigational, multicomponent, meningococcal serogroup B vaccine in healthy infants at 2, 4, and 6 months of age. Presented at: International Pathogenic Neisseria Conference; Sept 11-16, 2010; Banff, Canada. Esposito S, Vesikari T, Kimura A, et al. Tolerability of a three-dose schedule of an investigational, multicomponent, meningococcal serogroup B vaccine and routine infant vaccines in a lot consistency trial. Presented at: International Pathogenic Neisseria Conference; Sept 11-16, 2010; Banff, Canada. 9
10 MATS The Meningococcal Antigen Typing System MATS is based on a ELISA that measures the 3 recombinant protein antigens (fhbp, NadA, and NHBA) of 4CMenB against: Antigen quantity Similarity of strain antigens to vaccine antigens MATS links ELISA scores to hsba killing Developed using adult sera against a panel of 124 strains expressing a broad range of antigen variants; a subset of 57 strains were further tested using infant sera This allowed for the determination of the minimum amount of antigen measured by MATS needed to result in killing in the hsba assay Positive Bactericidal Threshold (PBT) PBT is established for the three recombinant protein antigens For PorA, conventional PCR genotyping is used to determine the similarity of the PorA gene sequence in the test strains to that in 4CMenB ELISA, enzyme-linked immunosorbent assay; fhbp, factor H-binding protein; hsba, human complement serum bactericidal assay; NadA, Neisserial adhesin protein A; NHBA, Neisseria Heparin Binding Protein; PorA, Porin A. Donnelly J, et al. PNAS. 2010;107:
11 MATS Results Correlate With hsba Infant pooled sera (13 months) Adult pooled sera # of strains tested Estimated killed in MATS Actual killed in hsba 1:8 77% 72% 74% 85% hsba, human complement serum bactericidal assay. Donnelly J, et al. PNAS. 2010;107:
12 MATS Allows for Systematic Estimation of 4CMenB Coverage for Any Given Region MATS methodology: Standardized and transferred across 5 reference laboratories Health Protection Agency, Institut Pasteur, Norwegian Institute of Public Health, University of Würzburg, Istituto Superiore di Sanità Transferred to 10 countries and transfer is ongoing in several more 12
13 4CMenB Has the Potential to Cover the Majority of MenB Strains in 5 European Countries Based on MATS, 4CMenB is predicted to cover 78% of strains 4CMenB European coverage estimates Norway: 85% [95% CI: 76%, 98%] n=41 England & Wales: 73% [59%, 88%] n=535 Germany: 82% [69%, 92%] n=222 France: 85% [70%, 93%] n=200 Italy: 87% [70%, 93%] n=54 Coverage based on MATS from pooled sera from 13-mo-old infants vaccinated at 2,4, 6, and 12 mo of age tested on 1,052 strains isolated during the epidemiological year. Boccadifuoco G, et al. Presented at: Meningitis and Septicaemia in Children and Adults 2011 (Organized by Meningitis Research Foundation); 8 9 November 2011; London, UK. Poster V36. 13
14 Proposed indications 4CMenB: Proposed Indications Population Age Dose series Infants 2 to 5 months 3 Interval 1 to 2 months Unvaccinated infants 6 to 11 months 2 2 months Unvaccinated toddlers and children Adolescents and adults 12 months to 10 years 11 years and older* months 1 to 2 months Booster recommended At 12 to 23 months At 12 to 23 months; 2 months from primary series *The safety and immunogenicity of 4CMenB in individuals older than 50 years have not been studied. 14
15 Summary Serogroup B meningococcal disease is a feared and often deadly disease, affecting mainly infants It is easily misdiagnosed, can kill within 24 hours of onset and may cause serious, life-long disabilities despite appropriate treatment 4CMenB includes 4 components that are important for the survival, function, and/or virulence of the meningococci: fhbp, NadA, NHBA, and PorA Use of multiple well-chosen antigens is likely to maximize coverage of genetically varied and changing strains Of note, 50% of MenB strains tested are covered by more than one 4CMenB antigen In clinical studies, 4CMenB has demonstrated a protective immune response in infants, children and adults In clinical studies, reactions seen after vaccination with 4CMenB were similar to those seen after vaccination with other routine vaccines 4CMenB is the first vaccine to demonstrate potential coverage of the majority of meningococcal serogroup B strains hereby helping to predict the public health impact of vaccination 15
Invasive Meningococcal Disease - prevention through vaccination
Invasive Meningococcal Disease - prevention through vaccination Dr Shamez Ladhani Paediatric Infectious Diseases Consultant Public Health England Email: shamez.ladhani@phe.gov.uk a pain you cannot describe
More informationMeningococcal vaccines and Herd protection. Potential Role, Coverage and Impact on carriage of the New Serogroup B protein vaccines in the Region
Meningococcal vaccines and Herd protection. Potential Role, Coverage and Impact on carriage of the New Serogroup B protein vaccines in the Region Ricardo Rüttimann Pediatric Infectious Diseases FUNCEI
More informationInvasive Meningococcal Disease - prevention through vaccination
Invasive Meningococcal Disease - prevention through vaccination Dr Shamez Ladhani Paediatric Infectious Diseases Consultant Public Health England Email: shamez.ladhani@phe.gov.uk a pain you cannot describe
More informationA combined approach to assess the potential coverage of a multicomponent protein-based vaccine
J prev med hyg 2012; 53: 56-60 Re v i e w A combined approach to assess the potential coverage of a multicomponent protein-based vaccine G. Boccadifuoco, B. Brunelli, M.G. Pizza, M.M. Giuliani Novartis
More informationPrevention of Meningococcal Disease. Marco Aurélio P. Sáfadi, MD, PhD FCM da Santa Casa de São Paulo
Prevention of Meningococcal Disease Marco Aurélio P. Sáfadi, MD, PhD FCM da Santa Casa de São Paulo Outline of the presentation Brief overview on the burden of MD Lessons learned with plain polysaccharide
More informationA Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
Drugs (2014) 74:15 30 DOI 10.1007/s40265-013-0155-7 REVIEW ARTICLE A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program Miguel O Ryan Jeffrey Stoddard Daniela
More informationMeningococci and meningococcal disease
Australian Technical Advisory Group on Immunisation (ATAGI) Statement Advice for immunisation providers regarding the use of Bexsero a recombinant multicomponent meningococcal B vaccine (4CMenB) March
More informationESCMID Online Lecture Library. by author
Innovatative strategies for meningococcal vaccines Mariagrazia Pizza The Impact of Vaccines on Public Health Prague, March 24th, 2013 Neisseria meningitidis is a bacterium surrounded by a capsular polysaccharide
More informationInvasive Meningococcal Disease - prevention through vaccination
Invasive Meningococcal Disease - prevention through vaccination Dr Shamez Ladhani Paediatric Infectious Diseases Consultant Public Health England Email: shamez.ladhani@phe.gov.uk Vaccines against MenB
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 25 June 2014 BEXSERO suspension for injection in prefilled syringe B/1 0.5 ml glass prefilled syringe with needle
More informationBiology of Neisseria meningitidis: implications for vaccine development Richard Moxon: University of Oxford
Biology of Neisseria meningitidis: implications for vaccine development Richard Moxon: University of Oxford Biology of N.meningitidis infection Within hours, the disease may progress to shock with multi-organ
More informationThe routine infant meningococcal B (MenB) vaccine against meningitis and septicaemia
The routine infant meningococcal B (MenB) vaccine against meningitis and septicaemia In the UK and Ireland babies are offered the MenB (meningococcal group B) vaccine, Bexsero, as part of the routine immunisation
More informationVaccines. Robert Read University of Southampton University Hospital Southampton
Vaccines Robert Read University of Southampton University Hospital Southampton Disclosures Non personal, non specific; Novartis-GSK Member, JCVI Editor in Chief, Journal of Infection, and Current Opinion
More informationEarly release, published at on September 23, Subject to revision.
Early release, published at www.cmaj.ca on September 23, 2013. Subject to revision. CMAJ Research Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal
More informationAn Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)
+ An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Advice for the use of the Multicomponent Meningococcal Serogroup B (4CMenB) Vaccine TO PROMOTE AND PROTECT THE
More information(Version 1.0, Dated 13 December 2013)
Preventing secondary cases of invasive meningococcal capsular group B disease: benefits of offering vaccination in addition to antibiotic chemoprophylaxis to close contacts of cases in the household, in
More informationAn Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Literature review on serogroup B invasive meningococcal
An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Literature review on serogroup B invasive meningococcal disease: epidemiology, multicomponent meningococcal B vaccine
More informationSee Spot Run Meningococcal update 2017
See Spot Run Meningococcal update 2017 Jim Buttery Infection and Immunity Monash Children s Hospital Monash Health Monash University SAEFVIC How serious a disease is N meningitidis? Meningococcal disease
More informationPfizer s Investigational Vaccine, rlp2086, for Invasive Meningococcal Serogroup B Disease
Pfizer s Investigational Vaccine, rlp2086, for Invasive Meningococcal Serogroup B Disease Laura J York, PhD Sr Director, International Scientific & Medical Affairs 1 Serogroup B is now the predominant
More informationS404- Meningococcal Vaccines: Updated Policy Statement 2014
S404- Meningococcal Vaccines: Updated Policy Statement 2014 Michael T. Brady, MD Associate Medical Director Nationwide Children s Hospital Columbus, Ohio Disclosure of Relevant Relationship Dr. Brady (or
More informationArticles. Funding Public Health England, GlaxoSmithKline.
Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007 08 and
More informationOutsourcing in Clinical Trials 1-2 July 2015
Outsourcing in Clinical Trials 1-2 July 2015 Innovating Dr Chris Bailey Babraham Research Campus Babraham Cambridge CB22 3AT UK +44 (0)1223 496115 Vaccines www.immbio.com 1 Utilising Academia for the Benefit
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BEXSERO safely and effectively. See full prescribing information for BEXSERO. BEXSERO (Meningococcal
More informationPRODUCT MONOGRAPH BEXSERO. Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) BEXSERO Suspension for Injection
PRODUCT MONOGRAPH BEXSERO Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) BEXSERO Suspension for Injection Active Immunizing Agent for the Prevention of Meningococcal Disease ATC Code: J07AH09
More informationBEXSERO contains the excipients sodium chloride, histidine, sucrose, and water for injections.
Page 1 of 18 NAME OF THE MEDICINE BEXSERO suspension for injection Multicomponent Meningococcal group B Vaccine (recombinant, adsorbed) Pharmacotherapeutic group: Meningococcal vaccines, ATC code: J07AH09.
More informationArticles. Funding Public Health England.
Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study Sydel R Parikh, Nick J Andrews, Kazim Beebeejaun,
More informationMulticomponent Meningococcal group B Vaccine (recombinant, adsorbed) Pharmacotherapeutic group: Meningococcal vaccines, ATC code: J07AH09.
Page 1 of 21 NAME OF THE MEDICINE BEXSERO suspension for injection Multicomponent Meningococcal group B Vaccine (recombinant, adsorbed) Pharmacotherapeutic group: Meningococcal vaccines, ATC code: J07AH09.
More informationPRODUCT MONOGRAPH BEXSERO. Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) BEXSERO Suspension for Injection
PRODUCT MONOGRAPH BEXSERO Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) BEXSERO Suspension for Injection Active Immunizing Agent for the Prevention of Meningococcal Disease ATC Code: J07AH09
More informationImmunization Update 2015
Immunization Update 2015 William Atkinson, MD, MPH* California Immunization Coalition Summit Riverside, California April 26, 2015 *Representing the Immunization Action Coalition, Saint Paul, MN Advisory
More informationHans Jürgen Dornbusch
Epidemiology of Invasive Meningococcal Disease Hans Jürgen Dornbusch Infectious Vaccination Disease Working Working Group Group Severe bacterial infections Pneumococcus Haemophilus influenzae b 3 rd World!
More informationImmunogenicity of a Meningococcal B Vaccine during a University Outbreak
The new england journal of medicine Original Article Immunogenicity of a Meningococcal B Vaccine during a University Outbreak Nicole E. Basta, Ph.D., Adel A.F. Mahmoud, M.D., Ph.D., Julian Wolfson, Ph.D.,
More informationBexsero (Meningococcal Group B Vaccine)
Bexsero (Meningococcal Group B Vaccine) Approved in More Than 35 Countries The two decade journey to bring Bexsero to Market Exploratory Pre-Clinical Development of a meningococcal group B vaccine was
More informationBCHOOSE TO VACCINATED. Ask your doctor about the MenB * vaccine.
BCHOOSE TO VACCINATED Vaccinate against meningococcal disease caused by Neisseria meningitidis group B strains (MenB) with BEXSERO BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed)
More informationBackground In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) convened a meningococcal subcommittee to conduct a comprehensive and
Background In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) convened a meningococcal subcommittee to conduct a comprehensive and detailed assessment of the evidence on the meningococcal
More informationBacterial diseases caused by Streptoccus pneumoniae in children
Bacterial diseases caused by Streptoccus pneumoniae in children Bactermia 85% Bacterial pneumonia 66% Bacterial meningitis 50% Otitis media 40% Paranasal sinusitis 40% 0% 10% 20% 30% 40% 50% 60% 70% 80%
More informationPediatric and Adolescent Vaccines
Pediatric and Adolescent Vaccines Andrea A. Berry, M.D. Division of Infectious Diseases and Tropical Pediatrics Center for Vaccine Development & Division of Malaria Research Overview Pediatric vaccine
More informationNeisseria meningitidis B vaccines
Expert Review of Vaccines ISSN: 1476-0584 (Print) 1744-8395 (Online) Journal homepage: http://www.tandfonline.com/loi/ierv20 Neisseria meningitidis B vaccines Donatella Panatto, Daniela Amicizia, Piero
More informationAUSTRALIAN PRODUCT INFORMATION. BEXSERO (multicomponent meningococcal group b vaccine) suspension for injection
AUSTRALIAN PRODUCT INFORMATION BEXSERO (multicomponent meningococcal group b vaccine) suspension for injection 1 NAME OF THE MEDICINE Multicomponent Meningococcal group B Vaccine (recombinant, adsorbed)
More informationInvasive meningococcal disease
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Invasive meningococcal disease Key facts In 2015, 3 121 confirmed cases of invasive meningococcal disease were reported by 30 EU/EEA Member States
More informationESCMID Online Lecture Library
What would be the best schedule for prevention of meningococcal disease in all ages? Ray Borrow ray.borrow@phe.gov.uk Public Health England, Manchester, UK MCC vaccine programme - UK In November 1999,
More informationSwiss National Reference Center for Meningococci. > 2014 Annual Report <
Swiss National Reference Center for Meningococci > 2014 Annual Report < Hp. Hinrikson, S. Emonet and J. Schrenzel* Hôpitaux Universitaires de Genève Laboratoire de Bactériologie Rue Gabrielle-Perret-Gentil
More informationMeningococcal disease and vaccination in the UK
Meningococcal disease and vaccination in the UK Ray Borrow Professor of Vaccine Preventable Diseases, Vaccine Evaluation Unit, Health Protection Agency, Manchester Royal Infirmary, Manchester, U.K. ray.borrow@hpa.org.uk
More informationHemagglutinin Neuraminidase
Evolving Vaccine Guidance: Influenza, Meningococcal & HPV Vaccines H. Cody Meissner, M.D. Professor of Pediatrics Tufts University School of Medicine Maine Chapter AAP Bar Harbor, Maine October 16, 2016
More informationMeningococcal vaccine evolution*
J prev med hyg 2012; 53: 131-135 through childhood to a peak in 19-year-olds, who have a carriage rate of 20%, and declines in adulthood [7, 8]. Based on the chemical composition of the polysaccharide
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME NEW ZEALAND DATA SHEET BEXSERO Multicomponent Meningococcal group B Vaccine (recombinant, adsorbed) 0.5 ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5
More informationImmunisation against meningococcal B disease for infants aged from two months. Information for registered health care practitioners
Draft 6thJuly Immunisation against meningococcal B disease for infants aged from two months Information for registered health care practitioners Disclaimer These draft training resources have been prepared
More informationImmunizations June 5, Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR
Immunizations June 5, 2015 Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR Disclosures None Goals Understand basic public health impact of immunization Recognize types
More informationDisclosure Statement. Encapsulated Bacteria. Functions of the Spleen 10/25/2017. Pharmacist Learning Objectives
Pharmacist Learning Objectives No Spleen? No Problem. A Review of Vaccinations Indicated for the Asplenic Patient SCSHP Fall Meeting October 26, 2017 Explain the rationale for vaccinations in Select the
More informationWHAT S NEW WITH VACCINATIONS IN 2016?
WHAT S NEW WITH VACCINATIONS IN 2016? MenB and a Few Other Changes Lynn Bahta, RN, PHN Immunization Clinical Consultant Minnesota Department of Health May 2016 Disclosure No conflict of interest Will discuss
More informationImmunization Update 2015
Immunization Update 2015 William Atkinson, MD, MPH Immunization Action Coalition Kentucky Immunization Conference Louisville, Kentucky October 14, 2015 Information in this presentation are valid as of
More informationArticles. Funding Novartis Vaccines and Diagnostics.
Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of
More informationBackground Rationale of resource Please note:
Background In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) convened a meningococcal subcommittee to conduct a comprehensive and detailed assessment of the evidence on the meningococcal
More informationChanges to the Meningococcal C conjugate (MenC) vaccine schedule. Questions and Answers
Changes to the Meningococcal C conjugate (MenC) vaccine schedule Questions and Answers Background The meningococcal C (MenC) vaccination programme was first introduced into the UK routine immunisation
More informationInvasive meningococal diseasefocus on Meningococcal B - epidemiology, international and Ireland
Invasive meningococal diseasefocus on Meningococcal B - epidemiology, international and Ireland Dr Suzanne Cotter, Health Protection Surveillance Centre (HPSC) Scope presentation Meningococccal disease
More informationImmunization-Preventable Outbreaks, Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Health Care Agency May 5, 2014
Immunization-Preventable Outbreaks, 2014 Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Health Care Agency May 5, 2014 Outbreaks to Cover Meningococcus group B Pertussis Mumps
More informationSCIENTIFIC ADVICE. Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA.
SCIENTIFIC ADVICE Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA www.ecdc.europa.eu ECDC SCIENTIFIC ADVICE Expert opinion on the introduction of the meningococcal
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 October 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 October 2009 MENINGITEC suspension for injection in prefilled syringes meningococcal group C oligosaccharide conjugate
More informationJ. D. HOLMES 1 *, D. MARTIN 2,C.RAMSAY 3,E.YPMA 4 AND P. OSTER 5. (Accepted 19 June 2007; first published online 3 August 2007)
Epidemiol. Infect. (2008), 136, 790 799. f 2007 Cambridge University Press doi:10.1017/s0950268807009211 Printed in the United Kingdom Combined administration of serogroup B meningococcal vaccine and conjugated
More informationNHS public health functions agreement Service specification No. 31 Meningococcal group B (MenB) programme
NHS public health functions agreement 2017-18 Service specification No. 31 Meningococcal group B (MenB) programme Classification: official NHS public health functions agreement 2017-18 Service specification
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rdna, component, adsorbed) 2. QUALITATIVE
More information2015 ACIP Immunization Schedules & Recommendations and MDPH Updates
Massachusetts Department of Public Health Division of Epidemiology and Immunization 2015 ACIP Immunization Schedules & Recommendations and MDPH Updates Susan M. Lett, MD, MPH Medical Director, Immunization
More informationRecommendations for the production and control of group C meningococcal conjugate vaccines
Technical Report Series No. 1 Recommendations for the production and control of group C meningococcal conjugate vaccines Addendum 2003 The Expert Committee on Biological Standardization, at its fifty-second
More information1.3 Meningococcal Disease (Neisseria meningitidis) (invasive)
1.3 Meningococcal Disease (Neisseria meningitidis) (invasive) Summary Number of cases, 214: 82 Number of cases, 213: 81 Number of cases, 212: 66 Crude incidence rate, 214:1.8/1, Between and 212, a marked
More informationSerogroup W in Africa & travellers
Serogroup W in Africa & travellers Muhamed-Kheir TAHA Institut Pasteur 01/11/2016 2 childhood meningococcal meningitis caused by this serogroup. Three infants, two with bacteremia and one with septic arthritis
More informationNHS public health functions agreement
NHS public health functions agreement 2016-17 Service specification No. 31 Meningococcal group B (MenB) programme Classification: official NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationSwiss National Reference Center for Meningococci. > 2015 Annual Report <
Swiss National Reference Center for Meningococci > 2015 Annual Report < Hp. Hinrikson, S. Emonet and J. Schrenzel* Hôpitaux Universitaires de Genève Laboratoire de Bactériologie Rue Gabrielle-Perret-Gentil
More informationChanges to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25 An update for registered
Changes to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25 An update for registered healthcare practitioners Frequently asked questions August
More informationExperience with Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) in Adolescent Vaccine Programs in the United States and Canada
Experience with Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) in Adolescent Vaccine Programs in the United States and Canada Jessica MacNeil, MPH Epidemiologist Centers for Disease Control and
More informationImmunisation against meningococcal B for infants aged from two months. Immunisation against meningococcal B disease for infants aged from two months
Immunisation against meningococcal B disease for infants aged from two months 1 Acknowledgement: This resource has been adapted with permission from Public Health England and Health Protection Scotland.
More informationHuman Vaccines & Immunotherapeutics. ISSN: (Print) X (Online) Journal homepage:
Human Vaccines & Immunotherapeutics ISSN: 2164-5515 (Print) 2164-554X (Online) Journal homepage: https://tandfonline.com/loi/khvi20 Safety and immunogenicity of a meningococcal B recombinant vaccine when
More informationVaccine Update Paul A. Offit, MD Division of Infectious Diseases Vaccine Education Center The Children
Vaccine Update Paul A. Offit, MD Division of Infectious Diseases Vaccine Education Center The Children s Hospital of Philadelphia Perelman School of Medicine The University of Pennsylvania Topics Hep A:
More information2017 Vaccine Preventable Disease Summary
2017 Vaccine Preventable Disease Summary Prepared 12251 James Street Holland, MI 49424 www.miottawa.org/healthdata October 2018 2017 Summary of Vaccine Preventable Diseases in Ottawa County This is a detailed
More informationHaemophilus influenzae type B and Hib Vaccine Chapter 9
Haemophilus influenzae type B and Hib Vaccine Chapter 9 Haemophilus influenzae Aerobic gram-negative bacteria Polysaccharide capsule Six different serotypes (a-f) of polysaccharide capsule 95% of invasive
More information9/12/2018. Meningococcal Disease and Meningococcal Vaccine. Neisseria meningitidis. Meningococcal Disease Pathogenesis. Aerobic gram-negative bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Meningococcal Disease and Meningococcal Vaccine Adult Track Chapter 14 Photographs and images included
More informationDevelopment of a Group A meningococcal conjugate vaccine for sub-saharan Africa: clinical trial results
Development of a Group A meningococcal conjugate vaccine for sub-saharan Africa: clinical trial results Global Immunization Meeting 2009, United Nations HQ New York City, February 2009 MenA conjugate vaccine
More informationImmunisation Update for Occupational Health
Immunisation Update for Occupational Health Dr Gayatri Amirthalingam Immunisation, Hepatitis & Blood Safety department Public Health England 29 th April 2016 Session Outline Epidemiology of vaccine preventable
More informationPreteen and teen vaccines: what to do with the recent recommendations
Preteen and teen vaccines: what to do with the recent recommendations MARK H. SAWYER UCSD SCHOOL OF MEDICINE RADY CHILDREN S HOSPITAL SAN DIEGO Continuing Education The Illinois Chapter, American Academy
More informationWHO Position Paper on Meningococcal Vaccines, Nov 2011
WHO Position Paper on Meningococcal Vaccines, Nov 2011 Extended list of references and summaries for the position paper and associated grading Tables Advisory Committee on Immunization Practices (ACIP).
More informationInsert Date Insert Medical Director Name Insert Insurance Company Insert Address Insert City, State, ZIP
Sample Letter of Medical Necessity (Physician letterhead) Insert Date Insert Medical Director Name Insert Insurance Company Insert Address Insert City, State, ZIP RE: Patient Name: XXXXX XXXXX, Policy
More informationMeningococcal Update. Disclosure. Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting
1 Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting 2 Disclosure Speakers Bureau: Sanofi Pasteur Vaccines and Novartis! I do not intend to discuss an unapproved/
More informationAUSTRALIAN PRODUCT INFORMATION - TRUMENBA (Meningococcal group B vaccine) suspension for injection pre-filled syringe
AUSTRALIAN PRODUCT INFORMATION - TRUMENBA (Meningococcal group B vaccine) suspension for injection pre-filled syringe 1. NAME OF THE MEDICINE Meningococcal group B vaccine. 2. QUALITATIVE AND QUANTITATIVE
More informationHaemophilus influenzae
Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology clarified in 1930s Haemophilus influenzae
More informationAnnex 3 Recommendations for the production and control of group C meningococcal conjugate vaccines (Addendum 2003)
World Health Organization WHO Technical Report Series, No. 926, 2004 Annex 3 Recommendations for the production and control of group C meningococcal conjugate vaccines (Addendum 2003) At its fifty-second
More informationImpact of meningococcal C conjugate vaccine in the UK
J. Med. Microbiol. Vol. 51 (22), 717 722 # 22 Society for General Microbiology ISSN 22-2615 REVIEW ARTICLE Impact of meningococcal C conjugate vaccine in the UK P. BALMER, R. BORROW and E. MILLER Meningococcal
More informationAn AW outer membrane vesicle (OMV) meningococcal vaccine trial in Ethiopia. Tesfamariam Mebrahtu Armauer Hansen Research Insitute
An AW outer membrane vesicle (OMV) meningococcal vaccine trial in Ethiopia Tesfamariam Mebrahtu Armauer Hansen Research Insitute BACKGROUND meningitis belt In the meningitis belt of sub-saharan Africa
More informationTRUMENBA (Meningococcal Group B Vaccine) Suspension for intramuscular injection Initial U.S. Approval: 2014
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRUMENBA safely and effectively. See full prescribing information for TRUMENBA. TRUMENBA (Meningococcal
More informationFULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRUMENBA safely and effectively. See full prescribing information for TRUMENBA. TRUMENBA (Meningococcal
More informationDecision-making for introduction of meningococcal vaccines in the face of changing meningococcal epidemiology
Decision-making for introduction of meningococcal vaccines in the face of changing meningococcal epidemiology Wiebke Hellenbrand Frankfurt, November 1, 2016 Evidence-based approach to vaccination recommendations
More information5/14/2015. Meagan Burns, MPH Massachusetts Adult Immunization Conference April relevant conflict. Grant Research/Support
Meagan Burns, MPH Massachusetts Adult Immunization Conference April 2015 Consultant Grant Research/Support Speaker s Bureau Major Stockholder Other Financial or Material Interest Off Label Use of Vaccines
More informationTable Of Content. Invasive Bacterial Infections Surveillance in the European Union... 2 Summary... 3 Coordinator, Leader contact and partners...
Table Of Content Invasive Bacterial Infections Surveillance in the European Union... 2 Summary... 3 Coordinator, Leader contact and partners... 5 National School of Public Health... 5 National Institute
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on CPS Meningococcal Vaccination These podcasts are designed to give medical students an overview of key topics in pediatrics.
More informationBabyJabs Vaccines. All vaccines are mercury- free We use aluminium- free vaccines wherever possible
BabyJabs Vaccines All vaccines are mercury- free We use aluminium- free vaccines wherever possible BabyJabs is a dedicated children s immunisation service, offering a choice of single and small combination
More informationImmunisation against Meningococcal B Disease for infants aged from two months
Immunisation against Meningococcal B Disease for infants aged from two months An update for Registered Healthcare Practitioners Sep 2018 Background In 2010, the Joint Committee on Vaccination and Immunisation
More informationPneumococcal Disease and Pneumococcal Vaccines
Pneumococcal Disease and Epidemiology and Prevention of - Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at
More informationMENINGOCOCCAL DISEASE IN NEW ZEALAND: the science, the art and the denouement
MENINGOCOCCAL DISEASE IN NEW ZEALAND: the science, the art and the denouement Diana Lennon Professor of Population Child & Youth Health University of Auckland DMID International Research in Infectious
More informationNeisseria meningitidis; clones, carriage, and disease
REVIEW 10.1111/1469-0691.12647 Neisseria meningitidis; clones, carriage, and disease R. C. Read Clinical and Experimental Sciences and NIHR Respiratory Biomedical Research Unit, Faculty of Medicine, University
More informationInvasive meningococcal disease (IMD) is a serious infection
Consensus A Consensus Statement: Meningococcal Disease Among Infants, Children and Adolescents in Latin America Ricardo Walter Rüttimann, MD,* Angela Gentile, MD, Mercedes Macias Parra, MD, Xavier Saez-Llorens,
More informationMDPH Clinical Update Adult Coalition
Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences MDPH Clinical Update Adult Coalition 1-9-2018 Susan M. Lett, MD, MPH Medical Director, Immunization Program
More informationMeningococcal vaccines
Meningococcal vaccines Rodolfo Villena, MD Pediatric Infectious Diseases Hospital de niños Dr. Exequiel González Cortés Universidad de Chile Clínica Las Condes Disclosures Speaker at sponsored training
More informationBenefits of the pneumococcal immunisation programme in children in the United Kingdom
Benefits of the pneumococcal immunisation programme in children in the United Kingdom 2006-2014 Professor Mary P E Slack mpeslack@gmail.com March 2015 Disclosure of interest The presenter has received
More information